# OnCo record sacituzumab-tirumotecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sacituzumab-tirumotecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sacituzumab-tirumotecan" ;
  schema:name "Sacituzumab tirumotecan"@en ;
  schema:description "Sacituzumab tirumotecan is a TROP2 antibody-drug conjugate approved for specific advanced breast- and lung-cancer settings in China. It remains investigational in the United States."@en ;
  schema:url <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  schema:dateModified "2026-10-06"^^xsd:date ;
  schema:citation <https://www.prnewswire.com/news-releases/kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-sac-tmt-approved-for-marketing-by-nmpa-of-china-for-2l-advanced-or-metastatic-tnbc-302317233.html>, <https://www.prnewswire.com/news-releases/kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-sac-tmt-approved-for-marketing-in-second-indication-by-nmpa-for-egfrm-nsclc-302396917.html>, <https://en.kelun-biotech.com/newsCenter.aspx?mid=18&page=5>, <https://www.prnewswire.com/news-releases/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hrher2--breast-cancer-302681155.html>, <https://www.merck.com/research/product-pipeline/>, <https://doi.org/10.1038/s41591-025-03630-w> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  onco:approval "China 2024: Adults with unresectable locally advanced or metastatic TNBC after at least two systemic therapies, including at least one for advanced or metastatic disease", "China 2025: Adults with EGFR-mutated locally advanced or metastatic nonsquamous NSCLC after EGFR-TKI therapy and platinum-based chemotherapy", "China 2025: Adults with EGFR-mutated locally advanced or metastatic nonsquamous NSCLC progressing after EGFR-TKI therapy", "China 2026: Adults with unresectable or metastatic HR-positive/HER2-negative breast cancer after endocrine therapy and at least one chemotherapy line in advanced disease" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/>, <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/t030/>, <https://onco.cc/terms/hydrophilic-next-gen/> ;
  onco:trials <https://onco.cc/trials/nct06670196/>, <https://onco.cc/trials/nct06305754/>, <https://onco.cc/trials/nct06448312/>, <https://onco.cc/trials/nct07216703/>, <https://onco.cc/trials/nct07318558/>, <https://onco.cc/trials/nct06824467/>, <https://onco.cc/trials/nct06356311/>, <https://onco.cc/trials/nct06170788/>, <https://onco.cc/trials/nct06459180/>, <https://onco.cc/trials/nct06422143/>, <https://onco.cc/trials/nct06711900/>, <https://onco.cc/trials/nct06312137/>, <https://onco.cc/trials/nct06952504/>, <https://onco.cc/trials/nct06132958/>, <https://onco.cc/trials/nct05870319/>, <https://onco.cc/trials/nct06074588/>, <https://onco.cc/trials/nct04152499/>, <https://onco.cc/trials/nct05351788/>, <https://onco.cc/trials/nct05816252/>, <https://onco.cc/trials/nct07329322/>, <https://onco.cc/trials/nct06428409/>, <https://onco.cc/trials/nct06483334/>, <https://onco.cc/trials/nct06393374/>, <https://onco.cc/trials/nct06469944/>, <https://onco.cc/trials/nct07252739/>, <https://onco.cc/trials/nct06312176/>, <https://onco.cc/trials/nct07419295/>, <https://onco.cc/trials/nct06966700/>, <https://onco.cc/trials/nct07286149/>, <https://onco.cc/trials/nct05319730/>, <https://onco.cc/trials/nct06637423/>, <https://onco.cc/trials/nct07324629/>, <https://onco.cc/trials/nct06780111/>, <https://onco.cc/trials/nct06445972/>, <https://onco.cc/trials/nct06788912/>, <https://onco.cc/trials/nct06841354/> .